Oral Micronized Progesterone: Manufacturing, Supply & Shortage History

How Oral Micronized Progesterone Works

Oral micronized progesterone delivers bio-identical progesterone through a particle-size reduction process that makes the hormone absorbable from the gastrointestinal tract. Native progesterone crystals are poorly soluble in water and undergo rapid first-pass hepatic metabolism, which historically made oral delivery impractical. Micronization changed that equation.

The micronization process grinds progesterone crystals to particles smaller than 20 micrometers in diameter. This increases the surface-area-to-volume ratio, accelerating dissolution in the GI lumen. The micronized powder is then suspended in peanut oil inside soft gelatin capsules. Peanut oil serves as a lipophilic carrier that further enhances absorption by promoting lymphatic uptake and slowing gastric transit 1.

Once absorbed, progesterone binds to intracellular progesterone receptors in target tissues, particularly the endometrium. It converts proliferative endometrium (driven by estrogen) to a secretory state, preventing unopposed estrogen-driven hyperplasia. This mechanism is the primary clinical rationale for its use in combined hormone replacement therapy (HRT). The PEPI Trial (N=875) demonstrated that oral micronized progesterone at 200 mg/day for 12 days per cycle provided endometrial protection comparable to medroxyprogesterone acetate (MPA) 10 mg/day while producing a more favorable lipid profile, specifically preserving HDL cholesterol gains from estrogen therapy 2.

Peak serum progesterone levels after a 200 mg oral dose typically reach 17-28 ng/mL within 2-3 hours, though individual variation is wide. Hepatic first-pass metabolism generates active metabolites including allopregnanolone, a neurosteroid with GABAergic sedative properties. This is why bedtime dosing is standard. The sedation is a feature for patients with menopausal insomnia. It can be a limiting side effect for others.

The Manufacturing Process: From Plant to Capsule

Progesterone USP starts as diosgenin, a steroidal sapogenin extracted from wild yam (Dioscorea species) or soybeans. The Marker degradation process, first developed by Russell Marker in the 1940s, converts diosgenin to progesterone through a series of chemical steps. Most global API production occurs in China and India, with a smaller number of facilities in Europe 3.

The synthesis pathway involves hydrolysis of diosgenin's side chain, followed by oxidation steps that yield progesterone as a crystalline powder. This raw progesterone must then pass USP specifications for identity, purity (typically ≥97%), heavy metals, residual solvents, and microbial limits before it qualifies as pharmaceutical-grade API.

Micronization happens at specialized facilities using jet milling or ball milling equipment. The target particle-size distribution must consistently fall below 20 micrometers, with typical D90 values (90th percentile particle diameter) around 10-15 micrometers. Quality control at this stage relies on laser diffraction particle-size analysis per USP <429>. Batch-to-batch consistency in particle size directly affects dissolution rate and bioavailability, making this step a critical quality attribute monitored under FDA's Current Good Manufacturing Practice (cGMP) requirements 4.

The micronized powder is blended into peanut oil to create a uniform suspension, which is then encapsulated in soft gelatin shells. Solvay (later Abbott, then AbbVie) manufactured the branded Prometrium product. Generic versions follow the same USP monograph but may use different encapsulation equipment, gelatin sources, or oil formulations, provided they demonstrate bioequivalence to the reference listed drug through pharmacokinetic studies filed with their Abbreviated New Drug Applications (ANDAs) 5.

A Timeline of Supply Disruptions

The U.S. progesterone capsule supply has experienced several documented shortages over the past decade. These events trace back to vulnerabilities common across generic hormone products: concentrated API sourcing, thin manufacturer margins, and demand that can shift rapidly with guideline changes.

2018 shortage. The FDA's Drug Shortage Database recorded a progesterone capsule shortage beginning in mid-2018, attributed to manufacturing delays at multiple generic producers. Teva Pharmaceuticals, one of the largest generic suppliers, reported intermittent supply gaps for both 100 mg and 200 mg strengths. Pharmacies in some regions reported weeks-long backorders 6.

2020 COVID-era disruption. The pandemic stressed pharmaceutical supply chains broadly, but progesterone faced compounding pressures. API shipments from China and India slowed during lockdowns. Simultaneously, telehealth prescribing for HRT increased as menopause and fertility patients shifted to remote consultations. FDA reported ongoing availability issues through Q3 2020 7.

2022-2024 intermittent regional shortfalls. While not triggering a formal national shortage listing for extended periods, distributors reported spot shortages in specific markets. Demand growth from expanded off-label use (including luteal phase support in fertility clinics and off-label use for sleep and anxiety) outpaced production capacity planning at some generic manufacturers.

Dr. JoAnn E. Manson, professor of medicine at Harvard Medical School, noted in a 2022 commentary: "The growing recognition of oral micronized progesterone's favorable safety profile relative to synthetic progestins has driven prescription volume beyond what supply chains were designed to handle" 8.

Why Shortages Recur: Supply Chain Anatomy

Several structural factors make oral micronized progesterone vulnerable to supply interruptions. The first is API concentration. An estimated 70-80% of global progesterone API originates from a small number of facilities in China and India. Regulatory actions, environmental shutdowns, or export restrictions at even one major facility can ripple through the finished-dose supply chain within weeks 9.

Generic economics create a second pressure point. Oral progesterone capsules are relatively low-cost products (wholesale acquisition cost around $0.50-$1.50 per capsule for generics). Thin margins discourage manufacturers from maintaining large safety stock or investing in redundant production lines. When a manufacturer exits the market or pauses production for equipment upgrades, the remaining suppliers cannot always absorb the volume quickly.

The peanut oil vehicle adds a third complication. Peanut oil is classified as a major allergen under FDA labeling rules, which has prompted some patients and prescribers to seek alternatives. Several compounding pharmacies offer progesterone capsules in olive oil or other vehicles, but these compounded versions are not FDA-approved and do not carry the same bioequivalence data. The Endocrine Society and the North American Menopause Society (NAMS) have both cautioned that compounded hormone preparations may have variable potency and purity 10.

A fourth factor is demand volatility. Progesterone prescribing has grown substantially since the 2002 Women's Health Initiative (WHI) findings shifted prescriber preference away from MPA and toward micronized progesterone. The NAMS 2022 position statement recommended oral micronized progesterone as the preferred progestogen for endometrial protection when used with estrogen therapy, further accelerating this shift 11.

Generic Market Structure and Current Manufacturers

Prometrium received FDA approval in 1998, and the first ANDA-based generics entered the market after Solvay's exclusivity periods expired. As of 2025, the ANDA holders for oral progesterone capsules (100 mg and 200 mg) include Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, Virtus Pharmaceuticals (a Lannett Company subsidiary), and several smaller generic firms 12.

The FDA's Orange Book lists Prometrium as the reference listed drug (RLD) with a therapeutic equivalence rating of "AB" for approved generics, meaning they are considered fully substitutable at the pharmacy level. Branded Prometrium is now marketed by AbbVie following their acquisition of Allergan, which had previously acquired the product through the Abbott/Solvay lineage.

Market consolidation is an ongoing concern. The generic progesterone capsule market in the U.S. has roughly 4-6 active manufacturers at any given time. Industry analyses suggest that when fewer than three manufacturers supply a given generic product, shortage risk increases substantially 13.

The FDA's 2019 report on drug shortage root causes identified three primary drivers: lack of incentives for manufacturers to produce less profitable drugs, market conditions that do not reward quality manufacturing, and logistical challenges in the supply chain. All three apply directly to oral micronized progesterone 14.

What Prescribers and Patients Can Do During Shortages

When supply tightens, clinical options exist. The first step is checking the FDA Drug Shortage Database at fda.gov/drugshortages for real-time status on progesterone capsules. Pharmacies can also query wholesaler availability across distributors; a product listed as backordered at one distributor may be available at another.

Therapeutic alternatives during true shortages include vaginal micronized progesterone (brand name Endometrin, or compounded vaginal suppositories), which bypasses first-pass metabolism and delivers progesterone directly to the uterus. A 2012 Cochrane review found that vaginal progesterone was effective for endometrial protection, though direct head-to-head data against oral micronized progesterone in the HRT setting remain limited 15.

For patients who cannot tolerate peanut oil, compounding pharmacies can prepare progesterone capsules in alternative oils. Prescribers should verify that the compounding pharmacy holds appropriate state board licensure and, ideally, PCAB accreditation or 503B outsourcing facility registration with the FDA.

NAMS guidelines recommend against abruptly discontinuing progesterone in women taking combined HRT, as the endometrial protection component is not optional. If oral progesterone becomes unavailable, switching to an alternative progestogen (vaginal progesterone, norethindrone acetate, or levonorgestrel-releasing IUD for endometrial protection) is preferable to dropping progestogen coverage entirely 16.

Quality Considerations Across Manufacturers

Not all generic progesterone capsules are manufactured identically, even though all must meet USP standards and demonstrate bioequivalence. Differences can exist in dissolution profiles within the allowed bioequivalence window (80-125% of the reference product's AUC and Cmax), excipient composition, and capsule shell characteristics.

Some patients report subjective differences when switching between generic manufacturers or between brand and generic. Whether these reflect true pharmacokinetic differences within the bioequivalence window or placebo/nocebo effects remains debated. A 2020 analysis published in the Journal of Clinical Pharmacology examined inter-generic variability for narrow therapeutic index drugs and found that real-world switching occasionally produced clinically meaningful serum level changes in sensitive patients 17.

For patients who report consistent problems with a specific generic manufacturer, prescribers can write "DAW-1" (dispense as written) for Prometrium or specify a preferred generic manufacturer on the prescription. Insurance coverage varies; some plans require prior authorization for brand-name Prometrium when a generic is available.

The Compounding Pharmacy Factor

Compounding pharmacies have become a significant supply source for progesterone, particularly in custom doses (25 mg, 50 mg, 150 mg) not available as FDA-approved products, in peanut-oil-free formulations, and as combination capsules with estradiol. The NAMS and Endocrine Society have expressed concern about the reliability of compounded hormone products, citing studies showing potency deviations of 10-50% from labeled dose in some compounded preparations 18.

The FDA distinguishes between traditional 503A compounding pharmacies (which fill individual patient prescriptions) and 503B outsourcing facilities (which can produce larger batches under more stringent FDA oversight). During shortages, 503B facilities may receive enforcement discretion from the FDA to produce drugs that are commercially available but temporarily in short supply.

Patients receiving compounded progesterone should request certificates of analysis for their specific batch and confirm that the pharmacy participates in independent potency testing programs. The goal is to maintain consistent progesterone exposure, as underdosed compounded progesterone could fail to protect the endometrium while overdosed preparations may increase sedation and side effects.

Looking Ahead: Supply Resilience Efforts

Several initiatives may improve supply stability for oral micronized progesterone. The FDA's Drug Competition Action Plan aims to accelerate ANDA approvals for products with fewer than three approved generic competitors. Progesterone capsules currently have enough ANDA holders, but the number of actively marketing manufacturers is what determines real supply resilience.

Domestic API manufacturing has also gained attention. The Biomedical Advanced Research and Development Authority (BARDA) and related federal programs have funded onshoring of API production for essential medications, though progesterone has not been specifically named as a priority molecule 19.

For now, the most practical approach for prescribers is to maintain awareness of supply conditions, keep compounding pharmacy relationships active as a backup, and educate patients that switching to a different generic manufacturer or route of administration may become necessary during shortage periods. Patients taking oral micronized progesterone for endometrial protection on combined HRT should fill prescriptions proactively and avoid waiting until the last day of their supply to refill. A 90-day supply through mail-order pharmacy, where insurance permits, provides a larger buffer against short-term disruptions.

The FDA Drug Shortage Staff can be contacted at drugshortages@fda.hhs.gov for real-time supply information not yet reflected in the public database.